JP6049712B2 - 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 - Google Patents

抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 Download PDF

Info

Publication number
JP6049712B2
JP6049712B2 JP2014520238A JP2014520238A JP6049712B2 JP 6049712 B2 JP6049712 B2 JP 6049712B2 JP 2014520238 A JP2014520238 A JP 2014520238A JP 2014520238 A JP2014520238 A JP 2014520238A JP 6049712 B2 JP6049712 B2 JP 6049712B2
Authority
JP
Japan
Prior art keywords
nanoparticles
group
bisphosphonate
metal
zol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014520238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520849A (ja
JP2014520849A5 (OSRAM
Inventor
リン ウェンビン
リン ウェンビン
リォウ デミン
リォウ デミン
デラロッカ ジョセフ
デラロッカ ジョセフ
エー クレーマー ステファニー
エー クレーマー ステファニー
ワイ プーン クリストファー
ワイ プーン クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2014520849A publication Critical patent/JP2014520849A/ja
Publication of JP2014520849A5 publication Critical patent/JP2014520849A5/ja
Application granted granted Critical
Publication of JP6049712B2 publication Critical patent/JP6049712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014520238A 2011-07-08 2012-07-09 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 Active JP6049712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505806P 2011-07-08 2011-07-08
US61/505,806 2011-07-08
PCT/US2012/045954 WO2013009701A2 (en) 2011-07-08 2012-07-09 Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders

Publications (3)

Publication Number Publication Date
JP2014520849A JP2014520849A (ja) 2014-08-25
JP2014520849A5 JP2014520849A5 (OSRAM) 2015-08-27
JP6049712B2 true JP6049712B2 (ja) 2016-12-21

Family

ID=47506842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520238A Active JP6049712B2 (ja) 2011-07-08 2012-07-09 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子

Country Status (4)

Country Link
US (3) US9693957B2 (OSRAM)
EP (2) EP3494974B1 (OSRAM)
JP (1) JP6049712B2 (OSRAM)
WO (1) WO2013009701A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517822B2 (en) 2013-11-06 2019-12-31 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
HK1166436A2 (en) * 2011-09-08 2012-10-26 Ybs Graphene Company Limited A method of forming a negative ion emitting product and a product formed by such method
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
CN105939699B (zh) 2013-12-03 2020-10-02 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
US10647733B2 (en) 2014-03-28 2020-05-12 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
WO2015149068A1 (en) 2014-03-28 2015-10-01 The University Of Chicago Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AP2017009766A0 (en) * 2014-08-14 2017-02-28 L E A F Holdings Group Llc Liposome encapsulated affinity drug
US10588564B2 (en) 2014-09-30 2020-03-17 Moein Health, LLC Method and kit for diagnosing and treating neoplastic tissue
WO2016057549A1 (en) 2014-10-06 2016-04-14 Aurasense Therapeutics, Llc Anti-tnf compounds
CN110731961A (zh) 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US10517924B2 (en) 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016172552A1 (en) * 2015-04-24 2016-10-27 Laderx Llc Metal complexes with bisphosphonate or pyrophosphate useful as imaging agents
JP6415715B2 (ja) 2015-09-30 2018-10-31 デューク・ユニヴァーシティ アスコルベート製剤及び造影剤としての使用方法
RU2657833C2 (ru) * 2015-12-01 2018-06-15 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение
WO2017120504A1 (en) * 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2017174969A1 (en) * 2016-04-08 2017-10-12 The University Of Birmingham Novel nanonization
AU2016403775B2 (en) * 2016-04-22 2021-10-14 Duke University Manganese complexes with substituted bisphosphonates useful as imaging and therapeutic agents
JP7090034B2 (ja) * 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
EA030671B1 (ru) 2016-07-20 2018-09-28 Общество С Ограниченной Ответственностью "Остерос Биомедика" Препарат для лечения костных поражений, вызванных злокачественными новообразованиями
CN108203448B (zh) * 2016-12-19 2020-12-15 香港中文大学 促进矿化并提供生物活性离子的持续释放的可注射水凝胶
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
JP7364552B2 (ja) 2017-08-02 2023-10-18 ザ ユニバーシティ オブ シカゴ Ｘ線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート
US20190314324A1 (en) * 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
US20210369876A1 (en) * 2018-10-16 2021-12-02 The Regents Of The University Of Colorado, A Body Corporate Chemiluminescent and fluorescent nanoparticle for optical imaging of cancer
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US20220370372A1 (en) * 2019-09-27 2022-11-24 Greenmark Biomedical Inc. Bisphosphonate loaded starch nanoparticle
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
US20230001396A1 (en) * 2019-11-14 2023-01-05 Board Of Regents, The University Of Texas System Compositions and methods for controlled delivery and protection of therapeutic agents
CN111420071A (zh) * 2020-03-27 2020-07-17 苏州欣影生物医药技术有限公司 一种纳米颗粒磁共振造影剂、制备方法及应用
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen
IT202000021292A1 (it) * 2020-09-09 2022-03-09 Consiglio Nazionale Ricerche Composizione in forma di polvere a base di microparticelle incorporanti nanoparticelle per la veicolazione di composti terapeutici/diagnostici
KR102514126B1 (ko) * 2020-12-24 2023-03-24 가톨릭대학교 산학협력단 히알루론산 나노입자를 유효성분으로 함유하는 전이성 골종양 광역학 치료용 조성물
CN114230610B (zh) * 2021-11-26 2023-05-23 西南医科大学附属医院 放射性标记物、其前体化合物、及制法和应用
US20250127719A1 (en) * 2021-12-07 2025-04-24 The Trustees Of The University Of Pennsylvania Anisamide-containing lipids and compositions and methods of use thereof
CN115501202B (zh) * 2022-10-12 2023-05-19 北京大学 一种递送过渡态唾液酸转移酶抑制剂的核壳纳米粒子及其制备方法和应用
WO2024236527A1 (en) * 2023-05-16 2024-11-21 Magvitae Innovations Inc A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof
IT202300015396A1 (it) * 2023-07-21 2025-01-21 Torino Politecnico Nanoparticelle rivestite e loro uso per il trasporto di agenti terapeutici e diagnostici
WO2025077898A1 (en) * 2023-10-13 2025-04-17 The Chinese University Of Hong Kong A therapeutic nucleic acid-encased nanoworm for gene delivery and endosomal escape

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61351A (en) 1980-10-27 1983-12-30 Yeda Res & Dev Organometallic polymers,their preparation and compositions of co-ordination compounds containing them
US5147806A (en) 1988-04-29 1992-09-15 Igen, Inc. Method and apparatus for conducting electrochemiluminescence measurements
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
AU8418891A (en) 1990-07-26 1992-02-18 Monsanto Company Novel polyamines and method for preparation thereof
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
US5641623A (en) 1995-01-04 1997-06-24 Martin; Mark T. Electrochemiluminescence assay
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5648508A (en) 1995-11-22 1997-07-15 Nalco Chemical Company Crystalline metal-organic microporous materials
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
US6180082B1 (en) 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
AU3000800A (en) 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
US20020064520A1 (en) 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
US6602932B2 (en) 1999-12-15 2003-08-05 North Carolina State University Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US7374911B2 (en) 2000-12-21 2008-05-20 Labow Mark A Interleukin-1 related gene and protein
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
WO2002088148A1 (en) 2001-04-30 2002-11-07 The Regents Of The University Of Michigan Isoreticular metal-organic frameworks, process for forming the same, and systematic design of pore size and functionality therein,with application for gas storage
WO2003094767A1 (en) 2002-03-25 2003-11-20 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
AU2003220472A1 (en) * 2002-09-28 2004-04-19 Mcneil-Ppc, Inc. Modified release dosage form with two cores
WO2004028504A1 (en) 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage forms
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
KR100401335B1 (en) 2003-03-08 2003-10-10 Mijitech Co Ltd Metal nanoparticle surface-coated with silicon oxides and preparation thereof
US6878838B2 (en) * 2003-03-24 2005-04-12 The University Of North Carolina At Chapel Hill Chiral porous metal phosphonates for heterogeneous asymmetric catalysis
JP2006521367A (ja) 2003-03-26 2006-09-21 株式会社Ｌｔｔバイオファーマ ターゲッティングと徐放を目的とした静脈注射用ナノ粒子
EP1620079A1 (en) * 2003-04-03 2006-02-01 Semafore Pharmaceuticals, Inc. Bone targeting of biodegradable drug-containing nanoparticles
ATE466865T1 (de) 2003-05-09 2010-05-15 Univ Michigan Mofs mit einer hohen oberfläche und methode zu deren herstellung
JP4463274B2 (ja) * 2003-06-27 2010-05-19 明 小谷 ビスホスホネート錯体
JP2007500712A (ja) 2003-07-31 2007-01-18 スリーエム イノベイティブ プロパティズ カンパニー カプセル化および徐放のための組成物
WO2005030254A2 (en) 2003-09-23 2005-04-07 Light Sciences Corporation Conjugates for photodynamic therapy
WO2005048942A2 (en) 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US20050147963A1 (en) 2003-12-29 2005-07-07 Intel Corporation Composite organic-inorganic nanoparticles and methods for use thereof
US7430282B2 (en) 2004-03-29 2008-09-30 National Institute Of Radiological Sciences Heel effect compensation filter X-ray irradiator, X-ray CT scanner and method for X-ray CT imaging
US20070259966A1 (en) 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20070218049A1 (en) 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
AU2006215300C9 (en) * 2005-02-17 2010-05-06 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
CN1305937C (zh) 2005-02-25 2007-03-21 复旦大学 一种金属配位聚合物纳米结构材料的制备方法
JP2008533173A (ja) 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ビスホスホネート組成物
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
PE20070360A1 (es) 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
US7263170B2 (en) 2005-09-30 2007-08-28 Pellegrino Anthony J Radiation therapy system featuring rotatable filter assembly
US20070088161A1 (en) 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
EP1987043B1 (en) 2006-02-09 2015-05-27 Simon Fraser University Birefringent metal-containing coordination polymers
US20100189222A1 (en) 2006-02-16 2010-07-29 Steller Micro Devices Panoramic irradiation system using flat panel x-ray sources
KR100943923B1 (ko) 2006-03-17 2010-02-24 홍순해 킬레이팅 유기 고분자와 생물학적 금속으로 이루어진 나노입자, 그리고 ｅｐｒ 효과를 이용한 새로운 광범위 무독성항암제 및 그 제조 방법
US20090317335A1 (en) 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
GB0613362D0 (en) 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
WO2008010263A1 (fr) 2006-07-18 2008-01-24 Mitsubishi Electric Corporation Procédé de production d'une électrode pour le traitement de surface par décharge et procédé de traitement de surface par décharge
US7699099B2 (en) * 2006-08-02 2010-04-20 B.J. Services Company, U.S.A. Modified Christmas tree components and associated methods for using coiled tubing in a well
WO2008016172A1 (fr) 2006-08-04 2008-02-07 Kurume University Inhibiteur de métastase
US7985868B1 (en) 2006-11-01 2011-07-26 Sandia Corporation Hybrid metal organic scintillator materials system and particle detector
US20080124281A1 (en) 2006-11-29 2008-05-29 Board Of Regents, The University Of Texas System Nanotubular probes as ultrasensitive mr contrast agent
FR2910009B1 (fr) 2006-12-19 2009-03-06 Commissariat Energie Atomique Procede de preparation d'un film organique a la surface d'un support solide dans des conditions non-electrochimiques, su pport solide ainsi obtenu et kit de preparation
JPWO2008102632A1 (ja) 2007-02-21 2010-05-27 コニカミノルタエムジー株式会社 Ｘ線バンドパスフィルタ、ｘ線照射システム及びｘ線撮影システム
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
KR20090001013A (ko) 2007-06-29 2009-01-08 주식회사 웰스킨 인돌-3-알킬카복실산을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트
WO2009008345A1 (ja) * 2007-07-06 2009-01-15 Tmrc Co., Ltd. 金属錯体化合物、これを有効成分とする癌治療剤組成物および該金属錯体化合物用の中間体
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8691748B2 (en) 2007-09-25 2014-04-08 The Regents Of The University Of California Edible and biocompatible metal-organic frameworks
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
WO2009139939A2 (en) 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
WO2009114476A1 (en) 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
GB0807862D0 (en) 2008-04-29 2008-06-04 Uni I Oslo Compounds
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
WO2010065751A2 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
ES2381022T3 (es) 2008-12-19 2012-05-22 Biolitec Ag Nanopartículas de fosfato de calcio como vehículo de colorantes para la terapia fotodinámica
EP2445532A1 (en) 2009-04-24 2012-05-02 Socpra - Sciences Santé Et Humaines Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
MX2011012491A (es) 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
SG176528A1 (en) * 2009-06-05 2012-01-30 Univ Nanyang Tech Targetted drug delivery to the bone
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
WO2011049743A1 (en) 2009-10-06 2011-04-28 Stellarray, Inc. Self contained irradiation system using flat panel x-ray sources
WO2011044671A1 (en) 2009-10-16 2011-04-21 University Health Network Porphyrin nanovesicles
WO2011062503A1 (en) 2009-11-20 2011-05-26 Clavis Pharma As Parenteral formulations of gemcitabine derivatives
GB201013307D0 (en) 2010-08-09 2010-09-22 Univ St Andrews Anti-microbial metal organic framework
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
WO2012138419A1 (en) 2011-04-04 2012-10-11 Georgia Tech Research Corporation Mof nanocrystals
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
US20120301537A1 (en) 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
JP6076968B2 (ja) 2011-06-06 2017-02-08 ユニバーシティ・ヘルス・ネットワーク ポルフィリン−リン脂質コンジュゲートを合成する方法
EP2721032A4 (en) 2011-06-16 2014-11-05 Univ South Florida POLYHEDRIC CAGE WITH METAL OPORPHYRENE EQUIPMENT, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
HUE053321T2 (hu) 2011-08-23 2021-06-28 Yeda Res & Dev (Bakterio)klorofill fotoszenzitizátorok szembetegségek és rendellenességek kezelésére
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2013068965A2 (en) 2011-11-11 2013-05-16 Koninklijke Philips Electronics N.V. Lighting apparatus and manufacturing method for manufacturing the lighting apparatus
BR112014014412A2 (pt) 2011-12-16 2017-06-13 Nanobiotix nanopartículas compreendendo materiais metálicos e de óxido de háfnio, sua preparação e uso
US20130209755A1 (en) 2012-02-15 2013-08-15 Phillip Dene Hustad Self-assembled structures, method of manufacture thereof and articles comprising the same
AU2013274101B2 (en) 2012-06-15 2017-09-07 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
EP2944323B1 (en) 2013-01-11 2019-03-27 Dingfu Biotarget Co., Ltd Agents for treating tumours, use and method thereof
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
US10647733B2 (en) 2014-03-28 2020-05-12 The University Of Chicago Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
WO2015149068A1 (en) 2014-03-28 2015-10-01 The University Of Chicago Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis
CN110731961A (zh) 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2017023667A1 (en) 2015-07-31 2017-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immunostimulatory nanocarrier
US10953393B2 (en) 2015-10-12 2021-03-23 The University Of Chicago Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations
CN105457038A (zh) 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
JP7090034B2 (ja) 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
KR20190040257A (ko) 2016-08-18 2019-04-17 더 유니버서티 오브 시카고 고효율 유기 변환을 위한 금속 산화물-지지된 지구에 풍부한 금속 촉매
JP7364552B2 (ja) 2017-08-02 2023-10-18 ザ ユニバーシティ オブ シカゴ Ｘ線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
US12042788B2 (en) 2019-08-21 2024-07-23 The University Of Chicago Strongly Lewis acidic metal-organic frameworks for continuous flow catalysis
EP4138784A4 (en) 2020-05-22 2024-11-13 The University of Chicago ORGANOMETALLIC FRAMEWORKS FOR DELIVERY OF SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY PURPOSES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517822B2 (en) 2013-11-06 2019-12-31 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers

Also Published As

Publication number Publication date
US20200222321A1 (en) 2020-07-16
EP2729180A2 (en) 2014-05-14
EP2729180B1 (en) 2019-01-23
EP3494974A1 (en) 2019-06-12
US20140234210A1 (en) 2014-08-21
US10596116B2 (en) 2020-03-24
US20170333347A1 (en) 2017-11-23
JP2014520849A (ja) 2014-08-25
US9693957B2 (en) 2017-07-04
EP3494974B1 (en) 2023-10-18
EP2729180A4 (en) 2015-03-04
WO2013009701A2 (en) 2013-01-17
US11872311B2 (en) 2024-01-16
WO2013009701A3 (en) 2013-03-21
WO2013009701A9 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
JP6049712B2 (ja) 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
US20110135571A1 (en) Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
Gao et al. Multifunctional nanoparticle for cancer therapy
Qin et al. pH-responsive polymer-stabilized ZIF-8 nanocomposites for fluorescence and magnetic resonance dual-modal imaging-guided chemo-/photodynamic combinational cancer therapy
US10780045B2 (en) Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US10806694B2 (en) Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP7090034B2 (ja) 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
CN111194232B (zh) 纳米级金属有机层和金属有机纳米片
Wang et al. Cancer cell macrophage membrane camouflaged persistent luminescent nanoparticles for imaging-guided photothermal therapy of colorectal cancer
US20090317335A1 (en) Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
US20070218049A1 (en) Nanoparticle based photodynamic therapy and methods of making and using same
Zou et al. 68Ga-labeled magnetic-NIR persistent luminescent hybrid mesoporous nanoparticles for multimodal imaging-guided chemotherapy and photodynamic therapy
Le et al. Emerging NIR light-responsive delivery systems based on lanthanide-doped upconverting nanoparticles
TWI791640B (zh) 奈米載體、其製備方法、其用途及包括其的可注射的醫藥溶液
Abodunrin et al. Metal organic frameworks in photodynamic therapy of cancer: functional roles of active metal centres and integrated and loaded photosensitizers in the framework
Li et al. Reverse microemulsion-based synthesis of (bis) phosphonate–metal materials with controllable physical properties: An example using zoledronic acid–calcium complexes
Laurent et al. Minor changes in the macrocyclic ligands but major consequences on the efficiency of gold nanoparticles designed for radiosensitization
US20200000915A1 (en) Bismuth-Gadolinium Nanoparticles
Tan et al. The develop of persistent luminescence nanoparticles with excellent performances in cancer targeted bioimaging and killing: a review
Wang et al. Engineered upconversion nanoparticles for breast cancer theranostics
Wang et al. Novel Chemo-Photothermal Therapy in Hepatic Cancer Using Gemcitabine-Loaded Hyaluronic Acid Conjugated MoS2/ZnO Nanocomposites
Yen Terpolymer-Lipid Hybrid MnO2 Nanoparticles as Theranostic Agents for Improving Magnetic Resonance Imaging of Solid Tumors and Image-Guided Radiation Therapy of Glioblastoma Multiforme
Mukherjee Magnetic iron oxide based nanoparticles for cancer therapeutics
Della Rocca Hybrid Nanoparticles for Anticancer Drug Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161122

R150 Certificate of patent or registration of utility model

Ref document number: 6049712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250